A Cornucopia of siRNA- and RNAi-based Therapeutics in Development Show Promise Researchers from academia and industry will present the latest developments in the application of interference RNA (RNAi) ...

The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

RNA interference (RNAi) therapeutics have garnered significant attention in clinical research due to their potential for treating various diseases, including genetic disorders, viral infections and ...

Abundance of Vehicles Are in Development to Help Translate the Technology into Therapeutics Hailed as the breakthrough of the year in 2002 by Science, RNAi still holds promise as a powerful, novel ...

Host-induced gene silencing (HIGS) technology has emerged as a powerful alternative to chemical treatments for protecting plants from pathogens or pests. More than 170 HIGS studies have been published ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi (RNA interference) therapeutics company, announced today that the Company has submitted a Clinical ...

This article is part of a series on viroids. The first, which can be read here, gave an overview of what viroids are and how they replicate. The second article described the plant host range of ...

Nearly 1.3 billion adults around the world have clinically high blood pressure, many of whom may be unaware that they are living with this condition. Nearly 1.3 billion adults around the world have ...

The plant produces a small RNA precursor, either a long double-stranded RNA or a pre-microRNA, with sequence similarity to a fungal gene (1). Researchers have engineered the sequence into the genomes ...